RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE

Fusion Pharmaceuticals Net Income 2024

Fusion Pharmaceuticals Net Income

-123.55 M USD

Fusion Pharmaceuticals Dividend yield

Ticker

FUSN

ISIN

CA36118A1003

In 2024, Fusion Pharmaceuticals's profit amounted to -123.55 M USD, a 30.2% increase from the -94.9 M USD profit recorded in the previous year.

The Fusion Pharmaceuticals Net Income history

YEARNET INCOME (undefined USD)
2029e101.4
2028e-91.22
2027e-145.6
2026e-163.08
2025e-146.6
2024e-123.55
2023-94.9
2022-87.61
2021-81.05
2020-79.72
2019-16.19
2018-11.65
2017-6.26

Fusion Pharmaceuticals Aktienanalyse

What does Fusion Pharmaceuticals do?

Fusion Pharmaceuticals Inc is a biopharmaceutical company that specializes in the development of innovative cancer therapies. The company was founded in Canada in 2014 and has since pursued a unique approach to cancer treatment: targeted radiation therapy. Fusion Pharmaceuticals' business model is based on providing cancer patients with an effective and gentle alternative to conventional treatment methods. The company utilizes a novel technology that allows radioisotopes to be specifically targeted to cancer cells. This enables radiation to be applied directly to the affected areas without damaging healthy tissue. Fusion Pharmaceuticals specializes in the development of therapies for solid tumors. The company collaborates with various partners to offer a wide range of treatment options. The key products currently include: - FP-1001: This product is currently in Phase 1 clinical trials and is intended for the treatment of patients with solid tumors. FP-1001 combines a specific antibody molecule with the radioactive isotope Actinium-225 to selectively destroy cancer cells. - FP-2000: This product is currently in the preclinical phase and aims to provide an effective treatment for pancreatic cancer. FP-2000 combines a specific antibody molecule with the radioactive isotope Lutetium-177 and has the potential to improve the survival rate of patients with this severe disease. - FP-3000: This product is also in the preclinical phase and is intended for the treatment of prostate cancer. FP-3000 combines a specific antibody molecule with the radioactive isotope Copper-67 and has the potential to offer an effective alternative to conventional treatments such as chemotherapy. Fusion Pharmaceuticals has rapidly gained importance in recent years and has attracted numerous prestigious investors. These include Canadian investment firm OrbiMed Advisors LLC and renowned US biotechnology company Johnson & Johnson. The company has also received several awards, including the Innovation Award from the Canadian government in 2019. For the future, Fusion Pharmaceuticals plans to further expand its development pipeline and create new therapies for a wide range of cancer diseases. The company aims to provide cancer patients worldwide with new hope and an effective alternative to conventional treatment methods. Fusion Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Net Income Details

Understanding Fusion Pharmaceuticals's Profit Margins

The profit margins of Fusion Pharmaceuticals represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of Fusion Pharmaceuticals's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.

Year-to-Year Comparison

Evaluating Fusion Pharmaceuticals's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.

Impact on Investments

Fusion Pharmaceuticals's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.

Interpreting Profit Fluctuations

When Fusion Pharmaceuticals’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.

Frequently Asked Questions about Fusion Pharmaceuticals Stock

How much profit has Fusion Pharmaceuticals made this year?

Fusion Pharmaceuticals has made -123.55 M USD this year.

How has the profit developed compared to last year?

The profit has increased by 30.2% compared to last year increased

What impact do the earnings have on the shareholders?

An increase in earnings is usually seen as a positive indicator for shareholders as it means that the company is generating profits.

How does Fusion Pharmaceuticals publish its earnings?

Fusion Pharmaceuticals publishes its earnings in the form of quarterly or annual reports.

Which financial indicators are included in the quarterly or annual reports?

The quarterly or annual reports contain information about sales and profit, cash flow, balance sheet, and other fundamentals.

Why is it important for investors to know the earnings of Fusion Pharmaceuticals?

The profits of Fusion Pharmaceuticals are an important indicator of the financial health of the company and can help investors decide whether they want to invest in the company or not.

How can one learn more about the earnings of Fusion Pharmaceuticals?

You can learn more about the earnings of Fusion Pharmaceuticals by reviewing the quarterly or annual reports or following the company presentations.

How much dividend does Fusion Pharmaceuticals pay?

Over the past 12 months, Fusion Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Fusion Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Fusion Pharmaceuticals?

The current dividend yield of Fusion Pharmaceuticals is .

When does Fusion Pharmaceuticals pay dividends?

Fusion Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Fusion Pharmaceuticals?

Fusion Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Fusion Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Fusion Pharmaceuticals located?

Fusion Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Fusion Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Fusion Pharmaceuticals from 5/6/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 5/6/2024.

When did Fusion Pharmaceuticals pay the last dividend?

The last dividend was paid out on 5/6/2024.

What was the dividend of Fusion Pharmaceuticals in the year 2023?

In the year 2023, Fusion Pharmaceuticals distributed 0 USD as dividends.

In which currency does Fusion Pharmaceuticals pay out the dividend?

The dividends of Fusion Pharmaceuticals are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Fusion Pharmaceuticals

Our stock analysis for Fusion Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Fusion Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.